Volume 140, Issue 3 , Pages 667-676, September 2010
Tissue-engineered pro-angiogenic fibroblast scaffold improves myocardial perfusion and function and limits ventricular remodeling after infarction
Objective
Microvascular malperfusion after myocardial infarction leads to infarct expansion, adverse remodeling, and functional impairment. Native reparative mechanisms exist but are inadequate to vascularize ischemic myocardium. We hypothesized that a 3-dimensional human fibroblast culture (3DFC) functions as a sustained source of angiogenic cytokines, thereby augmenting native angiogenesis and limiting adverse effects of myocardial ischemia.
Methods
Lewis rats underwent ligation of the left anterior descending coronary artery to induce heart failure; experimental animals received a 3DFC scaffold to the ischemic region. Border-zone tissue was analyzed for the presence of human fibroblast surface protein, vascular endothelial growth factor, and hepatocyte growth factor. Cardiac function was assessed with echocardiography and pressure–volume conductance. Hearts underwent immunohistochemical analysis of angiogenesis by co-localization of platelet endothelial cell adhesion molecule and alpha smooth muscle actin and by digital analysis of ventricular geometry. Microvascular angiography was performed with fluorescein-labeled lectin to assess perfusion.
Results
Immunoblotting confirmed the presence of human fibroblast surface protein in rats receiving 3DFC, indicating survival of transplanted cells. Increased expression of vascular endothelial growth factor and hepatocyte growth factor in experimental rats confirmed elution by the 3DFC. Microvasculature expressing platelet endothelial cell adhesion molecule/alpha smooth muscle actin was increased in infarct and border-zone regions of rats receiving 3DFC. Microvascular perfusion was also improved in infarct and border-zone regions in these rats. Rats receiving 3DFC had increased wall thickness, smaller infarct area, and smaller infarct fraction. Echocardiography and pressure–volume measurements showed that cardiac function was preserved in these rats.
Conclusions
Application of a bioengineered 3DFC augments native angiogenesis through delivery of angiogenic cytokines to ischemic myocardium. This yields improved microvascular perfusion, limits infarct progression and adverse remodeling, and improves ventricular function.
CTSNet classification: 30, 31.2, 31.5, 38.2
Abbreviations and Acronyms: α-SMA, alpha smooth muscle actin, 3DFC, 3-dimensional human dermal fibroblast culture, dP/dt max, maximum rate of pressure rise, EDV, end-diastolic volume, ESV, end-systolic volume, HFSP, human fibroblast surface protein, HGF, hepatocyte growth factor, IU, intensity units, LAD, left anterior descending coronary artery, LV, left ventricular, LVID, left ventricular internal diameter, LVIDd, left ventricular end-diastolic diameter, LVIDs, left ventricular end-systolic diameter, PECAM, platelet endothelial cell adhesion molecule, SCID, severe combined immunodeficient, VEGF, vascular endothelial growth factor
To access this article, please choose from the options below
This work was supported in part by NIH R01 HL072812 (to Y.J.W.), NIH/TSFRE K08 HL072812 (to Y.J.W.), an ISHLT Research Fellowship Grant (to J.R.F. III), and NIH HL07843 (to J.R.F.).
Disclosures: None.
PII: S0022-5223(10)00024-3
doi:10.1016/j.jtcvs.2009.12.037
© 2010 The American Association for Thoracic Surgery. Published by Elsevier Inc. All rights reserved.
Volume 140, Issue 3 , Pages 667-676, September 2010
